|
| | 10300HB0002ham001 | - 2 - | LRB103 04457 KTG 57820 a |
|
|
1 | | a poisoned drug supply, with illicit fentanyl killing |
2 | | people using street-bought substances. With the increasing |
3 | | use of potent fentanyl in the illicit substance supply in |
4 | | Illinois, more lives will continue to be lost. |
5 | | (3) Nearly all witnessed opioid overdoses are |
6 | | reversible with the provision of oxygen, naloxone, and |
7 | | other emergency care. However, many people use drugs alone |
8 | | or use them with people who do not have naloxone and are |
9 | | not trained in overdose response. |
10 | | (4) Overdose prevention sites can save lives. Overdose |
11 | | prevention sites provide individuals with a safe, hygienic |
12 | | space to consume pre-obtained drugs and access to other |
13 | | harm reduction, treatment, recovery, and ancillary support |
14 | | services. |
15 | | (5) The goals of overdose prevention sites are: |
16 | | (A) Saving lives by quickly providing emergency |
17 | | care to persons experiencing an overdose. |
18 | | (B) Reducing the spread of infectious diseases, |
19 | | such as AIDS and hepatitis. |
20 | | (C) Reducing public injection of substances and |
21 | | discarded syringes in surrounding areas. |
22 | | (D) Linking those with substance use disorders to |
23 | | behavioral and physical health supports. |
24 | | (b) Definitions. As used in this Section: |
25 | | "Harm reduction" means a philosophical framework and set |
26 | | of strategies designed to reduce harm and promote dignity and |
|
| | 10300HB0002ham001 | - 3 - | LRB103 04457 KTG 57820 a |
|
|
1 | | well-being among persons and communities who engage in |
2 | | substance use. |
3 | | "Overdose prevention sites" or "OPS" means hygienic |
4 | | locations where individuals may safely consume pre-obtained |
5 | | substances. |
6 | | (c) Overdose prevention sites; licensure. The Department |
7 | | shall develop a pilot program aimed at saving the lives of |
8 | | people who use substances that shall include the establishment |
9 | | of at least one overdose prevention site. The pilot overdose |
10 | | prevention sites shall be exempt from the intervention |
11 | | licensure requirements under Section 15-10 for harm reduction |
12 | | services until the Department has adopted rules for harm |
13 | | reduction services. Overdose prevention sites shall offer |
14 | | people who are most likely to use drugs in public, unobserved, |
15 | | high-risk, and unsanitary locations a safe space to use |
16 | | pre-obtained substances and to connect with community supports |
17 | | or other existing treatment and recovery programs, harm |
18 | | reduction services, and health care. |
19 | | (d) Pilot overdose prevention sites shall abide by the |
20 | | following principles: |
21 | | (1) Nothing About Us Without Us: OPS programs and |
22 | | services shall be formulated with transparency, community |
23 | | involvement, and direct input by people who use |
24 | | substances. |
25 | | (2) Equity: OPS staff and programs shall provide equal |
26 | | support, services, and resources to all participants and |
|
| | 10300HB0002ham001 | - 4 - | LRB103 04457 KTG 57820 a |
|
|
1 | | ensure accessibility to the greatest extent possible. |
2 | | (3) Harm Reduction: OPS programs and services shall |
3 | | prioritize individual dignity and autonomy in |
4 | | decision-making while encouraging people to reduce |
5 | | high-risk behaviors. |
6 | | (4) OPS programs and services shall affirm the |
7 | | humanity and dignity of people who use substances and |
8 | | shall be operated in a way that is safe, clean, inclusive, |
9 | | and welcoming to reduce stigma and build trust. |
10 | | (5) OPS programs and services shall prioritize |
11 | | relationship-building and trust among staff and |
12 | | participants in order to create safe spaces and provide |
13 | | increased opportunities to connect with additional |
14 | | services that promote health and well-being. |
15 | | (e) Staffing. |
16 | | (1) OPS staff, at a minimum, shall consist of trained |
17 | | peers with lived experience of substance use or overdose, |
18 | | along with other necessary professionals such as community |
19 | | health workers, behavioral health professionals, |
20 | | physicians, nurses, or medical personnel who have been |
21 | | trained in overdose responses. |
22 | | (2) A majority of the OPS staff shall include peers. |
23 | | (3) Staffing decisions must ensure that participants |
24 | | utilize the service, feel safe, and are connected to |
25 | | resources. |
26 | | (4) The Department may not prohibit persons with |
|
| | 10300HB0002ham001 | - 5 - | LRB103 04457 KTG 57820 a |
|
|
1 | | criminal records from frontline, management, or executive |
2 | | positions within entities that operate an overdose |
3 | | prevention site. |
4 | | (f) Location. Pilot overdose prevention sites shall be |
5 | | established in physical locations with high need determined by |
6 | | rates of overdoses and substance use; and as a natural |
7 | | development or extension of existing harm reduction and |
8 | | outreach programming. Priority shall be given to communities |
9 | | that have the highest number of fatal and non-fatal overdoses |
10 | | as determined by public health data from the Department of |
11 | | Public Health. Pilot overdose prevention sites shall |
12 | | specifically target high-risk and socially marginalized drug |
13 | | users in a municipality with a population greater than |
14 | | 2,000,000, not to exceed 12 months from implementation. |
15 | | (g) Pilot OPS features. An overdose prevention site shall |
16 | | at a minimum: |
17 | | (1) provide a hygienic space where participants may |
18 | | consume their pre-obtained substances; |
19 | | (2) administer first aid, if needed, and monitor |
20 | | participants for potential overdose; |
21 | | (3) provide sterile injection or other substance use |
22 | | supplies, collect used hypodermic needles and syringes, |
23 | | provide secure hypodermic needle and syringe disposal |
24 | | services; |
25 | | (4) provide access to naloxone or naloxone nasal |
26 | | spray; |
|
| | 10300HB0002ham001 | - 6 - | LRB103 04457 KTG 57820 a |
|
|
1 | | (5) ensure confidentiality of OPS participants by |
2 | | using an anonymous unique identifier; |
3 | | (6) provide education on safe consumption practices, |
4 | | proper disposal of hypodermic needles and syringes, and |
5 | | overdose prevention, including written information in, at |
6 | | a minimum, the 4 most commonly spoken languages in the |
7 | | State as determined by the Department; |
8 | | (7) provide referrals to substance use disorder and |
9 | | mental health treatment services, medication-assisted |
10 | | treatment or recovery services, recovery support services, |
11 | | medical services, job training and placement services, and |
12 | | other services that address social determinants of health; |
13 | | (8) provide wound kits; |
14 | | (9) offer a space on-site for participants to stay |
15 | | safely sheltered and supervised after consuming |
16 | | substances; and |
17 | | (10) provide adequate staffing by health care |
18 | | professionals or other trained staff. |
19 | | (h) Other OPS program designs and implementation shall be |
20 | | informed by the target community. |
21 | | (i) The Department may approve an entity to operate a |
22 | | pilot program in one or more jurisdictions upon satisfaction |
23 | | of the requirements set forth in this Section. The Department |
24 | | shall establish standards for program approval and training. |
25 | | (j) Notwithstanding the Illinois Controlled Substances |
26 | | Act, the Drug Paraphernalia Control Act, or any other |
|
| | 10300HB0002ham001 | - 7 - | LRB103 04457 KTG 57820 a |
|
|
1 | | provision of law to the contrary, the following persons shall |
2 | | not be arrested, charged, or prosecuted for any criminal |
3 | | offense or be subject to any civil or administrative penalty, |
4 | | including seizure or forfeiture of assets or real property or |
5 | | disciplinary action by a professional licensing board, or be |
6 | | denied any right or privilege, solely for participation or |
7 | | involvement in a program approved by the Department under this |
8 | | Act: |
9 | | (1) any individual who seeks to utilize, utilizes, or |
10 | | has utilized services provided at an overdose prevention |
11 | | site established in accordance with this Section; |
12 | | (2) a staff member or administrator of an overdose |
13 | | prevention site, including a healthcare professional, |
14 | | manager, employee, or volunteer; and |
15 | | (3) an individual who owns real property at which an |
16 | | overdose prevention site is located or operates.
|
17 | | (20 ILCS 301/15-10)
|
18 | | Sec. 15-10. Licensure categories and services. No person , |
19 | | entity, or program may provide the
services or conduct the |
20 | | activities described in this Section without first
obtaining a |
21 | | license therefor from the Department, unless otherwise |
22 | | exempted under this Act. The Department shall, by
rule, |
23 | | provide requirements for each of the following types of |
24 | | licenses and categories of service: |
25 | | (a) Treatment: Categories of service authorized by a |
|
| | 10300HB0002ham001 | - 8 - | LRB103 04457 KTG 57820 a |
|
|
1 | | treatment license are Early Intervention, Outpatient, |
2 | | Intensive Outpatient/Partial Hospitalization, Subacute |
3 | | Residential/Inpatient, and Withdrawal Management. |
4 | | Medication assisted treatment that includes methadone used |
5 | | for an opioid use disorder can be licensed as an adjunct to |
6 | | any of the treatment levels of care specified in this |
7 | | Section. |
8 | | (b) Intervention: Categories of service authorized by |
9 | | an intervention license are DUI Evaluation, DUI Risk |
10 | | Education, Designated Program, Harm Reduction Services, |
11 | | and Recovery Homes for persons in any stage of recovery |
12 | | from a substance use disorder.
|
13 | | The Department may, under procedures established by rule |
14 | | and upon a showing
of good cause for such, exempt off-site |
15 | | services from having to obtain a
separate license for services |
16 | | conducted away from the provider's licensed location.
|
17 | | (Source: P.A. 100-759, eff. 1-1-19 .)".
|